• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Thailand·Consumer Cyclical·JSP.BK
Share

JSP Pharmaceutical Manufacturing Stocks

THB 1.85Last Updated 12.06.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

THB 24.19M

THB 1.85
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 2005 and headquartered in Bangkok, Thailand, JSP Pharmaceutical Manufacturing (Thailand) Public Co., Ltd. specializes in providing contract manufacturing services. The company produces a diverse range of products, including dietary supplements, cosmetics, herbal remedies, nutritional products, and pharmaceutical goods within Thailand. Beyond manufacturing, JSP also offers comprehensive support services, encompassing research and development, packaging solutions, and regulatory registration assistance for both pharmaceuticals and dietary supplements. Additionally, the firm manufactures various cleaning products, such as hand sprays and specialized pharmaceutical sanitizers.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.06.2026 15:01

"A premium for candor": how top executives' comments affect companies' share prices

13.06.2026 22:31

U.S. and Iran to sign agreement on June 14, Strait of Hormuz to reopen - Trump

13.06.2026 16:01

Small caps last week: Record biotech IPO, Wizz Air's solid top line, SpaceX effect

13.06.2026 13:01

An investment idea for all times, IPO of the year and how to keep emotions in check in the stock market

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026